IP Library Granted Patent US 8,540,985
Granted Patent B2
US 8,540,985 · App. 13/001,316 · Granted Sep 24, 2013

Use of Hsp70 as a regulator of enzymatic activity

Inventors: Thomas Kirkegaard Jensen (Frederiksberg C, DK); Marja Helena Jaattela (København Ø, DK)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,540,985
App. No.
13/001,316
Granted
Sep 24, 2013
Kind
B2
Abstract

The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.

Claims (11)

1. A method for treatment of a lysosomal storage disorder selected from the group consisting of Niemann-Pick type A, Niemann-Pick type B, Niemann-Pick type C and Niemann-Pick type D, comprising the administration of a bioactive agent selected from Hsp70, a functional fragment of Hsp70 or variant thereof having at least 95% sequence identity to Hsp70, to an individual in need thereof.

2. The method according to claim 1 , wherein said bioactive agent is formulated as a pharmaceutical composition.

3. The method according to claim 1 , wherein said lysosomal storage disorder is characterised as having residual enzymatic activity of the defective enzyme involved in the disease pathology.

4. The method according to claim 1 , wherein said Hsp70, or functional fragment or variant thereof, has 100% identity to wild-type Hsp70 protein.

5. The method according to claim 1 , wherein said bioactive agent is Hsp70.

6. The method according to claim 1 , wherein said Hsp70 is full length Hsp70.

7. The method according to claim 1 , wherein said bioactive agent is a functional fragment or variant of Hsp70 having at least 95% sequence identity to Hsp70 .

8. The method according to claim 1 , wherein said functional fragment or variant of Hsp70 comprises all or part of the ATPase domain of Hsp70.

9. The method according to claim 1 , wherein said functional fragment or variant of Hsp70 comprises tryptophan at amino acid position 90 of the Hsp70 ATPase domain.

10. The method according to claim 1 , wherein said Hsp70, or a functional fragment or variant thereof, is recombinant Hsp70 (rHsp70).

11. The method according to claim 1 , wherein said Hsp70 is derived from a mammal selected from the group consisting of human (homo sapiens), mouse (mus musculus), cow, dog, rat, ferret, pig, sheep, and monkey.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 4, 2024
From: KREOS CAPITAL VI (UK) LIMITED
To: ZEVRA DENMARK A/S (F/K/A KEMPHARM DENMARK A/S, SUCCESSOR IN INTEREST TO ORPHAZYME A/S)
Reel/Frame 067007/0706 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2024
From: KEMPHARM DENMARK A/S
To: ZEVRA DENMARK A/S
Reel/Frame 066539/0204 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2022
From: ORPHAZYME A/S
To: KEMPHARM, INC.
Reel/Frame 060592/0646 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2022
From: KEMPHARM, INC.
To: KEMPHARM DENMARK A/S
Reel/Frame 060592/0595 →
SECURITY INTEREST Recorded Sep 6, 2019
From: ORPHAZYME A/S; ORPHAZYME US, INC.
To: KREOS CAPITAL VI (UK) LIMITED
Reel/Frame 050294/0026 →
CHANGE OF NAME Recorded Apr 11, 2018
From: ORPHAZYME APS
To: ORPHAZYME A/S
Reel/Frame 045911/0992 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF ASSIGNEE PREVIOUSLY RECORDED ON REEL 025803 FRAME 0876. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 28, 2011
From: JENSEN, THOMAS K.; JAATTELA, MARJA H.
To: ORPHAZYME APS
Reel/Frame 026034/0761 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2011
From: JENSEN, THOMAS K.; JAATTELA, MARJA H.
To: ORPHAZYME APS C/O COBIS A/S
Reel/Frame 025803/0876 →
Priority Claims (1)
DK 2008 00885 · Jun 26, 2008 · national
Continuity (1)
Related Publication 20110286993A1 · Nov 24, 2011